Abstract Search

ea0090p335 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Dapagliflozin Improves Glycemic control and Liver Function with Body Weight Loss as Add-on therapy to Metformin Plus Evogliptin: A 24-week, Randomized, Double-blind, Clinical Trial

Jeong In-Kyung , Mook Choi Kyung , Ah Han Kyung , Kim Kyoung-Ah , kim injoo , jin Han Seung , Wan Lee Byung , Lee Won-Young , Jib Yoo Soon

Background and aims: The efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control with evogliptin and metformin combinations was investigated.Materials and methods: Patients with HbA1c of 7.0% to 10.5% receiving evogliptin 5mg and metformin ≥1000 mg were randomized to receive dapagliflozin 10 mg/day (n=99) or placebo (n=99) for 24 weeks. The primary end...

2 shares

Endocrine Abstracts

Dapagliflozin Improves Glycemic control and Liver Function with Body Weight Loss as Add-on therapy to Metformin Plus Evogliptin: A 24-week, Randomized, Double-blind, Clinical Trial

BiosciAbstracts